Accessibility Gap Assessment

A structured evaluation of why a proven biological treatment is not reaching the patients who need it — and what it would take to close the gap.

What It Is

The distance between a successful clinical trial and widespread patient access is often measured in years and billions. This assessment maps that distance for a specific treatment: identifying the regulatory, manufacturing, logistical, and economic barriers that stand between laboratory proof and bedside reality.

We do not assume the gap is inevitable. We measure it, explain it, and propose how to close it.

What You Get

Access barrier inventory — every obstacle between approval and patient, categorized and ranked by impact
Geographic disparity map — where the treatment is available, where it is not, and why the difference exists
Manufacturing pathway analysis — can production scale to meet actual demand at a viable cost?
Regulatory comparison — approval timelines and requirements across target markets
Closure roadmap — a phased plan to reduce the accessibility gap, with cost estimates

Who It Serves

Pharmaceutical companies planning global launch strategies for biologics
Government health ministries prioritizing treatments for national formularies
International health organizations targeting treatment access in underserved regions
Foundations and NGOs funding treatment access programs